Clinical Trial: Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07816666) titled 'Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer' on Sept. 07.

Brief Summary: The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Study Start Date: Sept. 29

Study Type: INTERVENTIONAL

Condition: Platinum-sensitive Relapsed Epithelial Ovarian Cancer Platinum-sensitive Relapsed Fallopian Tube Cancer Platinum-sensitive Relapsed Primary Periton...